CD133

Phase 1Cell therapy

RRoyan Institute

CD133 is one of 70 biologic programs targeting Cerebral Palsy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

CirrhosisActive, not recruiting

Cerebral PalsyPhase 1

Active, not recruiting

CirrhosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Preclinical

2 2

HEPCLUDEX

Gilead

Preclinical

1 3

Farxiga

AstraZeneca

Preclinical

1 4

Thalomid

Bristol-Myers Squibb

Preclinical

1 5

Revia

Teva

Preclinical

1 6

Cipro

Bayer

Preclinical

1 7

Dobutrex

Eli Lilly

Preclinical

1 8

Azulfidine

Pfizer

Preclinical

1 9

Coreg

Akero Therapeutics

Preclinical

6 10

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stem Cells1 trial

Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients

Completed·RRoyan Institute·Phase 1/2·NCT01120925·30 enrolled

Cirrhosis1 trial

Autologous Bone Marrow Stem Cells in Cirrhosis Patients

Completed·RRoyan Institute·Phase 1/2·NCT00713934·7 enrolled

Cerebral Palsy1 trial

Side Effects of Bone Marrow Derived CD133 Transplantation in Cerebral Palsy

Completed·RRoyan Institute·Phase 1·NCT01404663·12 enrolled

Liver Metastases1 trial

Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.

Completed·HHospital San Carlos, Madrid·Phase 2·NCT03803241·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CD133. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD133 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD133. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Royan Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: RRoyan Institute

CD133

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stem Cells1 trial

Cirrhosis1 trial

Cerebral Palsy1 trial

Liver Metastases1 trial

References

Drug Info

Quick Facts

Related News